OmniAb, Inc.
Darlene Pedersen has a diverse work experience in the field of bioscience spanning over 17 years. Darlene is currently working as a Scientist at OmniAb, Inc. since November 2022. Prior to this, from August 2019 to November 2022, they worked as a Scientist at Ligand Pharmaceuticals. Before that, they held the position of Senior Research Associate at Ligand Pharmaceuticals from 2017 to August 2019. Darlene also worked as a Senior Research Associate at CRYSTAL BIOSCIENCE INC. from March 2017 to November 2017. Darlene served as the Manager of Cell Culture at Crystal Bioscience from January 2014 to March 2017. In addition, they worked as a Research Associate at CRYSTAL BIOSCIENCE INC. from June 2012 to December 2013. Darlene started their career in 2005 at OHSU, where they worked in the Embryonic Stem Cell Core Lab until September 2008.
Darlene Pedersen holds a Master's degree in Biochemistry and Molecular Biology, which they obtained from the University of California, Davis, from 2003 to 2005. Prior to that, they completed their Bachelor of Science in Biochemistry at San Francisco State University, studying from 2000 to 2002.
This person is not in the org chart
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.